Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

72 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-05-31

Study Completion Date

2012-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

According to the World Health Organization, lymphatic filariasis, a mosquito-borne parasitic disease, is the second leading cause of disability worldwide. Across 81 countries, approximately 120 million people are infected with the disease, and of those infected, an estimated 40% reside in India alone. The most disfiguring symptoms of lymphatic filariasis, elephantiasis and lymphedema, cause long-term suffering in patients who are then often embarrassed or even rejected from their communities. Because of the disease's debilitating physical and social effects on patients, this study will explore the intersection of disability and health-related quality of life (HRQoL) in lymphatic filariasis patients in India. Specifically, HRQoL and disability in lymphatic filariasis subjects and age- and gender- matched control subjects will be compared. Two HRQoL tools , the general Dermatology Life Quality Index (DLQI) and a disease-specific instrument developed by a dermatology group in India will be used to gauge HRQol. In addition, the demographic and disease-specific factors associated with HRQoL and disability in filarial lymphedema subjects will be identified.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Research for Elim of Filariasis

NCT00145223

W. Bancrofti Filariasis

COMPLETED

Parasitological Evaluation of Fascioliasis in Clinically Suspected Patients .

NCT03869788

Fascioliasis

UNKNOWN

Prevalence of LF Infection in Districts Not Included in LF Control Activities

NCT03131401

Lymphatic Filariases Onchocerciasis

COMPLETED

The Effect of Praziquantel Treatment on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria, Uganda

NCT00215267

Schistosomiasis Malaria

COMPLETED NA

Effect of Albendazole Dose on Clearance of Filarial Worms

NCT00339417

Lymphatic Filariasis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymphatic Filariasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lymphatic Filariasis

No interventions assigned to this group

Patients without Lymphatic Filariasis

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects with a clinical diagnosis of lymphatic filariasis
* Subjects over the age of 18 and able to give consent

* Subjects without a clinical diagnosis of lymphatic filariasis
* Subjects over the age of 18 and able to give consent

Exclusion Criteria

* Subjects on active treatment for lymphatic filariasis
* Subjects who are under the age of 18 or unable to give informed consent

* Subjects without a clinical diagnosis of lymphatic filariasis
* Subjects who are under the age of 18 or unable to give informed consent

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes